Pneumococcal vaccine development (Q35918513)

11 August 2017

1 reference

title

Pneumococcal vaccine development (English)

1 reference

11 August 2017

1 reference

Jan T Poolman

1

1 reference

11 August 2017

1 October 2004

1 reference

Expert Review of Vaccines

11 August 2017

1 reference

11 August 2017

3

1 reference

11 August 2017

5

1 reference

11 August 2017

597-604

1 reference

The classical pathway is the dominant complement pathway required for innate immunity to Streptococcus pneumoniae infection in mice

11 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.5.597

Antibody to capsular polysaccharide of Streptococcus pneumoniae at the time of hospital admission for Pneumococcal pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.5.597

Human immunoglobulin M memory B cells controlling Streptococcus pneumoniae infections are generated in the spleen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.5.597

Activation of neutrophils and inhibition of the proinflammatory cytokine response by endogenous granulocyte colony-stimulating factor in murine pneumococcal pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.5.597

Heptavalent pneumococcal conjugate vaccine: current and future impact

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.5.597

Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.5.597

Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate Vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.5.597

Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.5.597

Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.5.597

Effectiveness of pneumococcal polysaccharide vaccine in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.5.597

Review of pneumococcal conjugate vaccine in adults: implications on clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.5.597

Streptococcus pneumoniae colonisation: the key to pneumococcal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.5.597

Antibody-enhanced pneumococcal adherence requires IgA1 protease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.5.597

Upper and lower respiratory tract infection by Streptococcus pneumoniae is affected by pneumolysin deficiency and differences in capsule type.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.5.597

The immune response to pneumococcal proteins during experimental human carriage

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.5.597

Efficacy of a pneumococcal conjugate vaccine against acute otitis media

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.5.597

Effect of conjugate pneumococcal vaccine followed by polysaccharide pneumococcal vaccine on recurrent acute otitis media: a randomised study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.5.597

Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.5.597

Historical changes in pneumococcal serogroup distribution: implications for the era of pneumococcal conjugate vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.5.597

Ability of pneumococcal serotypes and clones to cause acute otitis media: implications for the prevention of otitis media by conjugate vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.5.597

Use of a whole genome approach to identify vaccine molecules affording protection against Streptococcus pneumoniae infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.5.597

Effects of PspA and antibodies to PspA on activation and deposition of complement on the pneumococcal surface

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.5.597

The innate immune response to pneumococcal lung infection: the untold story.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.5.597

Antibody response to pneumolysin and to pneumococcal capsular polysaccharide in healthy individuals and Streptococcus pneumoniae infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.5.597

Identification and characterization of a novel family of pneumococcal proteins that are protective against sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.5.597

Recombinant PhpA protein, a unique histidine motif-containing protein from Streptococcus pneumoniae, protects mice against intranasal pneumococcal challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.5.597

Prevention of pneumococcal disease in mice immunized with conserved surface-accessible proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.5.597

Protection against Streptococcus pneumoniae elicited by immunization with pneumolysin and CbpA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.5.597

Role of pneumococcal surface protein C in nasopharyngeal carriage and pneumonia and its ability to elicit protection against carriage of Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.5.597

Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.5.597

Highly reduced protection against Streptococcus pneumoniae after deletion of a single heavy chain gene in mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.5.597

Impact of Pneumococcal Vaccination on Morbidity and Mortality of Geriatric Patients: A Case-Controlled Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.5.597

Effect of Clonal and Serotype‐Specific Properties on the Invasive Capacity ofStreptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.5.597

Comparison of an Opsonophagocytic Assay and IgG ELISA to Assess Responses to Pneumococcal Polysaccharide and Pneumococcal Conjugate Vaccines in Children and Young Adults with Sickle Cell Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.5.597

21 January 2018

Identifiers

DOI

10.1586/14760584.3.5.597

1 reference

11 August 2017

1 reference

PubMed ID

15485339